Aurora Spine（ASAP.F）株式概要オーロラ・スパイン・コーポレーションは、子会社のオーロラ・スパイン社を通じて、カナダで低侵襲脊椎間固定システムと器具の開発と販売に従事している。 詳細ASAP.F ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性4/6配当金0/6報酬過去5年間の収益は年間9%増加しました。 リスク分析意味のある時価総額がありません ( $12M )すべてのリスクチェックを見るASAP.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW486,676 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINROAG486,676 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.1782.8% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2m34m2016201920222025202620282031Revenue US$34.2mEarnings US$4.4mAdvancedSet Fair ValueView all narrativesAurora Spine Corporation 競合他社Jin Medical InternationalSymbol: NasdaqCM:ZJYLMarket cap: US$15.0mPicard MedicalSymbol: NYSEAM:PMIMarket cap: US$15.5mIceCure MedicalSymbol: NasdaqCM:ICCMMarket cap: US$14.3mAspira Women's HealthSymbol: OTCPK:AWHLMarket cap: US$18.3m価格と性能株価の高値、安値、推移の概要Aurora Spine過去の株価現在の株価CA$0.1752週高値CA$0.2652週安値CA$0.15ベータ-0.551ヶ月の変化4.43%3ヶ月変化-15.70%1年変化-28.57%3年間の変化-19.90%5年間の変化-69.94%IPOからの変化-87.67%最新ニュースお知らせ • May 28Aurora Spine Corporation to Report Q1, 2026 Results on May 28, 2026Aurora Spine Corporation announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 28, 2026お知らせ • Apr 23Aurora Spine Corporation to Report Fiscal Year 2025 Results on Apr 29, 2026Aurora Spine Corporation announced that they will report fiscal year 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2026お知らせ • Apr 15Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026.お知らせ • Oct 28Aurora Spine Corporation Launches New Biologics PortfolioAurora Spine Corporation announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation. The establishment of Aurora Biologics creates seamless synergy across Aurora's growing spine ecosystem--including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™?, Hydra A.E.R.O.™?, DEXA™?, and SiLO™? portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity. Comprehensive Biologic Solutions: Aurora Biologics launches with a complete suite of allograft solutions, including: TURBO FUSE™? Fiber Putty - a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment. OSTEO GRAFT™? DBM Putty - a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers. OSTEO BRIDGE™? Sponge Strips - a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration. Each biologic is formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration. Engineered to work synergistically with Aurora's implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons.お知らせ • Sep 18Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion DeviceAurora Spine Corporation announced the official launch of its DEXA-L Anterior Lumbar Interbody Fusion Device, with the product being implanted in recent initial surgeries. DEXA-L is part of Aurora's patented DEXA Technology Platform, which is a series of products that are the world's first bone density matched implants. The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal implant that is a bone-mimicking™? structural implant helping doctors match the implant to the patient's bone density and quality. Dr. Daniel Barba of San Diego, CA was the first surgeon to use the DEXA-L™? Stand Alone ALIF System in the United States. Dr. Barba stated "Each of my patients are unique. Now I can use a Stand-Alone ALIF cage tailored specifically to their needs. This novel technology allows me to match the modulus of the cage to the bone density of each of my patients. This has enabled me to expand my indications for lumbar fusion within patients that would normally not be a good candidate due to their poor bone quality. The DEXA- L Stand Alone ALIF system, promoting bone density matched DEXA™? Technology, marks another landmark advancement for spinal surgery from Aurora Spine. The company are excited to introduce another procedural solution that accommodates not only standard spine patients but the most challenging patients who are also in need of care. Patient specific options for spine surgery have been advancing over the last several years but not matching a patient's bone density was a glaring need for a significant number of patients. The CDC estimates that almost half of the US population over 50 years of age have low bone mass. This equates to millions of patients that need an implant that matches their bone density when having spine surgery. The DEXA- Ltd. Stand Alone ALIF System now allows surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as those who have normal bone density but still need surgery. The days of not matching an implant modulus to the patient are behind the company.お知らせ • Jul 09Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion SystemAurora Spine Corporation announced initial surgeries using Aurora Spine's newest product, the AERO Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine. The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations.最新情報をもっと見るRecent updatesお知らせ • May 28Aurora Spine Corporation to Report Q1, 2026 Results on May 28, 2026Aurora Spine Corporation announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 28, 2026お知らせ • Apr 23Aurora Spine Corporation to Report Fiscal Year 2025 Results on Apr 29, 2026Aurora Spine Corporation announced that they will report fiscal year 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2026お知らせ • Apr 15Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026.お知らせ • Oct 28Aurora Spine Corporation Launches New Biologics PortfolioAurora Spine Corporation announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation. The establishment of Aurora Biologics creates seamless synergy across Aurora's growing spine ecosystem--including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™?, Hydra A.E.R.O.™?, DEXA™?, and SiLO™? portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity. Comprehensive Biologic Solutions: Aurora Biologics launches with a complete suite of allograft solutions, including: TURBO FUSE™? Fiber Putty - a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment. OSTEO GRAFT™? DBM Putty - a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers. OSTEO BRIDGE™? Sponge Strips - a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration. Each biologic is formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration. Engineered to work synergistically with Aurora's implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons.お知らせ • Sep 18Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion DeviceAurora Spine Corporation announced the official launch of its DEXA-L Anterior Lumbar Interbody Fusion Device, with the product being implanted in recent initial surgeries. DEXA-L is part of Aurora's patented DEXA Technology Platform, which is a series of products that are the world's first bone density matched implants. The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal implant that is a bone-mimicking™? structural implant helping doctors match the implant to the patient's bone density and quality. Dr. Daniel Barba of San Diego, CA was the first surgeon to use the DEXA-L™? Stand Alone ALIF System in the United States. Dr. Barba stated "Each of my patients are unique. Now I can use a Stand-Alone ALIF cage tailored specifically to their needs. This novel technology allows me to match the modulus of the cage to the bone density of each of my patients. This has enabled me to expand my indications for lumbar fusion within patients that would normally not be a good candidate due to their poor bone quality. The DEXA- L Stand Alone ALIF system, promoting bone density matched DEXA™? Technology, marks another landmark advancement for spinal surgery from Aurora Spine. The company are excited to introduce another procedural solution that accommodates not only standard spine patients but the most challenging patients who are also in need of care. Patient specific options for spine surgery have been advancing over the last several years but not matching a patient's bone density was a glaring need for a significant number of patients. The CDC estimates that almost half of the US population over 50 years of age have low bone mass. This equates to millions of patients that need an implant that matches their bone density when having spine surgery. The DEXA- Ltd. Stand Alone ALIF System now allows surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as those who have normal bone density but still need surgery. The days of not matching an implant modulus to the patient are behind the company.お知らせ • Jul 09Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion SystemAurora Spine Corporation announced initial surgeries using Aurora Spine's newest product, the AERO Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine. The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations.お知らせ • Jun 18Aurora Spine Corporation Announces the Upcoming Launch of DEXA-L™, A Standalone Anterior Lumbar Interbody Fusion (ALIF) System Built on the Same Award-Winning DEXA PlatformAurora Spine Corporation announced the upcoming fourth quarter 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis. For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density, where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation. DEXA Technology™ directly addresses this clinical gap, offering a smart, density-matched solution for today’s diverse patient population.お知らせ • May 20Aurora Spine Corporation to Report Q1, 2025 Results on May 22, 2025Aurora Spine Corporation announced that they will report Q1, 2025 results Pre-Market on May 22, 2025お知らせ • Apr 24Aurora Spine Corporation to Report Q4, 2024 Results on Apr 28, 2025Aurora Spine Corporation announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025お知らせ • Apr 15+ 1 more updateAurora Spine Corporation, Annual General Meeting, Jun 16, 2025Aurora Spine Corporation, Annual General Meeting, Jun 16, 2025.お知らせ • Apr 02Aurora Spine Corporation Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™? Sacroiliac Joint Fusion SystemAurora Spine Corporation announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in the journal Neurospine. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™? MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques. The SiLO TFX™? system is a minimally invasive solution designed for sacroiliac joint fusion, addressing conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw, and associated instrumentation, engineered to transfix the sacrum and ilium, thereby providing stability conducive to bony fusion. The SiLO TFX system is designed in accordance with the AO Principles of Fusion--providing mechanical stability, preserving vascular supply, minimizing soft tissue disruption, and promoting an optimal environment for bone healing by proper decortication and the use of bone graft. The study's findings indicate that the posterior interposition technique, as employed by the SiLO TFX system, removes less bone volume and offers a larger surface area for bony fusion compared to the posterolateral transosseal technique. Specifically, the posterior interposition technique resulted in a 42% +- 8% reduction in mutation/counternutation motion of the sacroiliac joint, outperforming the 14% +- 4% reduction observed with the posterolateral transosSEous technique. Furthermore, upon fatigue loading, the posterior interposition implant maintained the bone-implant interface across all specimens, whereas the posterolateral transos Seous implant inhibited migration or subsidence in 20%-50% of specimens.お知らせ • Mar 25Aurora Spine Corporation Announces FDA 510(K) Clearance for the Aero™? Facet Fusion SystemAurora Spine Corporation announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's newest product, the AERO™? Facet Fusion System. The AERO MIS Facet Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations. Initial surgeries utilizing the AERO system are expected to begin in late Third Quarter 2025, with several leading spine surgeons already selected to participate in an initial clinical study aimed at validating the device's clinical outcomes and long-term benefits.お知らせ • Mar 10Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE StudyAurora Spine Corporation announced the completion of patient enrollment in its REFINE study of its ZIP™ Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease. This prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care. The REFINE study, designed to bridge the gap between conservative treatments and more invasive surgical options, has successfully enrolled its full cohort of patients across multiple centers in the United States. Data from this pioneering study will be published out to one year, with a subsequent cohort publication extending to two years, offering robust, long-term insights into patient outcomes. The results will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025, spotlighting Aurora Spine's commitment to evidence-based innovation. Dr. Steven Anagnost, an orthopedic surgeon at Oklahoma Spine and Musculoskeletal Medicine, reflected this optimism: "The impact of the REFINE study cannot be overstated. As an orthopedic surgeon, I see firsthand the need for reliable, minimally invasive solut ions. This trial's comprehensive, multi-specialty approach will shape the future of spinal fusion, offering patients safer and more effective options backed by solid data." Dr. Jason Pope, a pain physician at Evolve Restorative Center in Santa Rosa, CA, highlighted the transformative potential of the study: "True innovation isn't just about new devices, it's about proving they work and delivering real benefits to patients. The REFINE study showcases how Aurora Spine is pushing boundaries, providing hope and tangible improvements for those suffering from debilitating back pain." Aurora Spine's REFINE study stands out for its collaborative design, uniting neurosurgeons, orthopedic surgeons, and interventional pain physicians to assess the ZIP™ MIS Interspinous Fusion System. This minimally invasive technology aims to address unmet needs in treating lumbar spinal stenosis and degenerative disc disease, offering patients a less invasive alternative to traditional spinal surgery. The Company anticipates that the REFINE study's findings will reinforce the efficacy and safety of its ZIP™ system, further solidifying Aurora Spine's position as a trailblazer in the spinal implant market. Aurora Spine remains committed to empowering physicians and improving patient outcomes through groundbreaking clinical evidence and minimally invasive solutions.お知らせ • Jan 23Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of SalesAurora Spine Corporation announced the promotion of Matt Paxton to Executive Vice President of Sales. As Executive Vice President of Sales, Mr. Paxton will spearhead company-wide initiatives, leveraging his expertise to drive operational excellence and strategic growth. Over the years, Mr. Paxton has demonstrated an unwavering commitment to Aurora Spine’s vision, playing a key role in fostering a culture of collaboration, innovation, and accountability.お知らせ • Oct 16Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar SystemAurora Spine Corporation announced it has launched its new OSTEO ONYX™ lumbar fusion system, promoting Rough Surface Technology (RST). The Hydra Osteo Onyx open and MIS systems give Surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as their healthier patients. The Osteo Onyx roughened surface technology provides a great purchase within the pedicle that creates a benefit to patients with osteoporosis or poor bone quality. In addition, the range of MIS screws (4.5mm up to 10.5mm) allow its to accommodate any patient with a minimally invasive procedure which leads to better patient recovery and satisfaction.お知らせ • May 01Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024Aurora Spine Corporation announced that they will report Q1, 2024 results on May 13, 2024お知らせ • Apr 23Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024.お知らせ • Jan 18Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual MeetingAurora Spine Corporation announced that it will be participating in the North American Neuromodulation Society (NANS) Annual Meeting from January 18-21 in Las Vegas, Nevada. The NANS Annual Meeting is a prominent medical conference that brings together healthcare professionals, researchers, and experts in the field of neuromodulation. Aurora will be showcasing two Sacroiliac Joint (SI Joint) fusion products. Silo TFX and Silo offer physicians options to stabilize the SI Joint, helping patients with access to treatment for their SI joint dysfunction. Aurora Spine will be presenting data from the recent publication of the first 6-month clinical evaluation from the REFINE Screwless™ ZIP™ Study of its ZIP Interspinous Fixation device in the Journal of Pain Research.お知らせ • Dec 04Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion ImplantAurora Spine Corporation announced the publication of the first 6-month clinical evaluation of its ZIP™? fusion implant in the Journal of Pain Research. Lumbar interlaminar decompression with interspinous fixation is an established safe and effective treatment for spinal stenosis. Early maintenance of improvements in pain intensity and function are critical for durability of symptom relief. The purpose of this study is to investigate the efficacy of minimally invasive treatments for low back pain during the early period after treatment and their utility in setting the course for longer term success. The scientific paper titled "Early Functional Outcomes in Low Back Pain Subjects with a Novel Interspinous fixation Device: REFINE Study 6-month Results", is a pivotal multi-center study of its ZIP™? InterspinousFixation device for patients suffering from back pain due to symptomatic degenerative disc disease and spinal stenosis. The REFINE Screwless™? ZIP Study utilized patient evaluations at 3- and 6-months following treatment and is part of an actively enrolling, institutional review board (IRB) approved, single-arm, multicenter, prospective, open-label 12-month study. Clinical efficacy was assessed primarily using the change from baseline in Oswestry Disability Index (ODI), Visual Analog Scale (VAS) of the back and leg pain during walking and standing, andurich Claudication Questionnaire (ZCQ), and secondarily using the Patient Global Impression of Change (PGIC) and Patient-Reported Outcomes Measurement Information System (PROMIS). This 6-month interim analysis at 42% enrollment of patients was conducted to determine prolonged safety and efficacy of the ZIP interspinous fusion device. Once in place, the device acts as a fusion support column to open the passageways that contain the spinal cord and nerve roots. This procedure may reduce the compression on the nerves, resulting in potential pain relief in the leg, groin, and buttocks, and then return to a more active lifestyle.お知らせ • Oct 24Aurora Spine Corporation announced that it has received CAD 1.933782 million in fundingAurora Spine Corporation announced a non-brokered private placement to issue 6,445,939 Units at a price of CAD 0.30 per Unit for the gross proceeds of CAD 1,933,781.7 on October 3, 2023. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each whole warrant is exercisable at a price of CAD 0.50 per common share for a period of 24 months following the date of issuance. In connection with the Offering, the Company paid finder's fees in the amount of CAD 50,700 in the aggregate. The securities issued under the Offering will be subject to a four-month hold period in accordance with applicable securities legislation. The Offering is subject to TSX Venture Exchange final approval. The transaction included participation from certain directors of the Company.お知らせ • Sep 14Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation SystemAurora Spine Corporation announced that it is in full commercial release of its proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device system. The patented, minimally invasive SiLO TFX MIS Sacroiliac Joint fixation System is intended for sacroiliac joint disruptions and degenerative sacroiliitis. The SiLO TFX MIS SacROiliac Joint Fixation System includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. The SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability forony fusion.お知らせ • Jun 29Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter StudyAurora Spine Corporation announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System. The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects. The DEXA-C system is indicated for anterior cervical interbody fusion procedures and is the first in a series of implants based on Aurora's patented DEXA™? technology platform. Based on the DEXA T-score for measuring a patient's bone density, the DEXA technology platform includes implants that are of varying densities to match a patient's bone density. DEXA-C is intended for use on patients who require anterior cervical discectomy and fusion surgery. The DEX A-C system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate.お知らせ • May 24Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023Aurora Spine Corporation announced that they will report Q1, 2023 results on May 24, 2023お知らせ • May 06Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023.株主還元ASAP.FUS Medical EquipmentUS 市場7D-1.5%2.0%-0.4%1Y-28.6%-19.5%18.4%株主還元を見る業界別リターン: ASAP.F過去 1 年間で-19.5 % の収益を上げたUS Medical Equipment業界を下回りました。リターン対市場: ASAP.Fは、過去 1 年間で18.4 % のリターンを上げたUS市場を下回りました。価格変動Is ASAP.F's price volatile compared to industry and market?ASAP.F volatilityASAP.F Average Weekly Movement9.0%Medical Equipment Industry Average Movement8.6%Market Average Movement7.3%10% most volatile stocks in US Market16.6%10% least volatile stocks in US Market3.2%安定した株価: ASAP.F 、 US市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: ASAP.Fの 週次ボラティリティ ( 9% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト2013n/aTrent Northcuttwww.aurora-spine.comオーロラ・スパイン社は、子会社のオーロラ・スパイン社を通じて、カナダで低侵襲の棘突起間固定システムと器具の開発と販売に従事している。同社は、変性椎間板疾患を患う患者向けに、ZIP、ZIP ULTRA、ZIP LP、ZIP-51などの棘突起間腰椎固定装置や、骨が成長して固定プロセスが完了するまでの間、椎骨間の間隔と安定性を提供するTiコーティングポリエーテルエーテルケトン体間ケージを提供している。また、骨成長用に無菌パックされたチタンプラズマスプレーコーティングの脊椎注入インプラントや、腰椎セクション用のEOS、VOX、Echo、Echo SD、EchoXLなどのインターボディ製品、頸椎処置用のDiscoveryも提供している。さらに、同社は前方腰椎椎体間固定術用3Dプリンターによるスタンドアローン型固定装置であるSOLOを提供している。SOLOはプレートとスペーサーが一体化したシステムであり、脊柱の支持と安定性を提供しながら自然な解剖学的プロフィールを維持するのに役立つ。さらに、頸椎椎体間固定装置DEXA-Cを提供している。DEXA-Cは、多孔質3Dプリント椎体間固定装置で、患者の骨質に合わせて低、中、高密度の格子パターンオプションを組み込んだもので、DEXA SOLO-L脊椎固定装置も提供している。同社は2013年に設立され、カナダのトロントに本社を置いている。もっと見るAurora Spine Corporation 基礎のまとめAurora Spine の収益と売上を時価総額と比較するとどうか。ASAP.F 基礎統計学時価総額US$12.30m収益（TTM）-US$584.30k売上高(TTM)US$18.39m0.7xP/Sレシオ-21.1xPER（株価収益率ASAP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計ASAP.F 損益計算書（TTM）収益US$18.39m売上原価US$6.97m売上総利益US$11.41mその他の費用US$12.00m収益-US$584.30k直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-0.0075グロス・マージン62.07%純利益率-3.18%有利子負債／自己資本比率79.5%ASAP.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/09 17:59終値2026/07/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Aurora Spine Corporation 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Neal GilmerClarus Securities Inc.
お知らせ • May 28Aurora Spine Corporation to Report Q1, 2026 Results on May 28, 2026Aurora Spine Corporation announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 28, 2026
お知らせ • Apr 23Aurora Spine Corporation to Report Fiscal Year 2025 Results on Apr 29, 2026Aurora Spine Corporation announced that they will report fiscal year 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2026
お知らせ • Apr 15Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026.
お知らせ • Oct 28Aurora Spine Corporation Launches New Biologics PortfolioAurora Spine Corporation announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation. The establishment of Aurora Biologics creates seamless synergy across Aurora's growing spine ecosystem--including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™?, Hydra A.E.R.O.™?, DEXA™?, and SiLO™? portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity. Comprehensive Biologic Solutions: Aurora Biologics launches with a complete suite of allograft solutions, including: TURBO FUSE™? Fiber Putty - a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment. OSTEO GRAFT™? DBM Putty - a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers. OSTEO BRIDGE™? Sponge Strips - a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration. Each biologic is formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration. Engineered to work synergistically with Aurora's implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons.
お知らせ • Sep 18Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion DeviceAurora Spine Corporation announced the official launch of its DEXA-L Anterior Lumbar Interbody Fusion Device, with the product being implanted in recent initial surgeries. DEXA-L is part of Aurora's patented DEXA Technology Platform, which is a series of products that are the world's first bone density matched implants. The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal implant that is a bone-mimicking™? structural implant helping doctors match the implant to the patient's bone density and quality. Dr. Daniel Barba of San Diego, CA was the first surgeon to use the DEXA-L™? Stand Alone ALIF System in the United States. Dr. Barba stated "Each of my patients are unique. Now I can use a Stand-Alone ALIF cage tailored specifically to their needs. This novel technology allows me to match the modulus of the cage to the bone density of each of my patients. This has enabled me to expand my indications for lumbar fusion within patients that would normally not be a good candidate due to their poor bone quality. The DEXA- L Stand Alone ALIF system, promoting bone density matched DEXA™? Technology, marks another landmark advancement for spinal surgery from Aurora Spine. The company are excited to introduce another procedural solution that accommodates not only standard spine patients but the most challenging patients who are also in need of care. Patient specific options for spine surgery have been advancing over the last several years but not matching a patient's bone density was a glaring need for a significant number of patients. The CDC estimates that almost half of the US population over 50 years of age have low bone mass. This equates to millions of patients that need an implant that matches their bone density when having spine surgery. The DEXA- Ltd. Stand Alone ALIF System now allows surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as those who have normal bone density but still need surgery. The days of not matching an implant modulus to the patient are behind the company.
お知らせ • Jul 09Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion SystemAurora Spine Corporation announced initial surgeries using Aurora Spine's newest product, the AERO Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine. The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations.
お知らせ • May 28Aurora Spine Corporation to Report Q1, 2026 Results on May 28, 2026Aurora Spine Corporation announced that they will report Q1, 2026 results at 9:30 AM, US Eastern Standard Time on May 28, 2026
お知らせ • Apr 23Aurora Spine Corporation to Report Fiscal Year 2025 Results on Apr 29, 2026Aurora Spine Corporation announced that they will report fiscal year 2025 results at 4:00 PM, US Eastern Standard Time on Apr 29, 2026
お知らせ • Apr 15Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026Aurora Spine Corporation, Annual General Meeting, Jun 17, 2026.
お知らせ • Oct 28Aurora Spine Corporation Launches New Biologics PortfolioAurora Spine Corporation announced the launch of Aurora Biologics, a new division dedicated to advancing spinal fusion success through best-in-class biologic innovation. The establishment of Aurora Biologics creates seamless synergy across Aurora's growing spine ecosystem--including its renowned interspinous, lumbar, and sacroiliac fusion systems such as ZIP™?, Hydra A.E.R.O.™?, DEXA™?, and SiLO™? portfolios. These mechanical and regenerative technologies now converge within one integrated platform designed to enhance patient outcomes, improve surgical efficiency, and promote long-term fusion integrity. Comprehensive Biologic Solutions: Aurora Biologics launches with a complete suite of allograft solutions, including: TURBO FUSE™? Fiber Putty - a bone graft substitute composed of demineralized bone fibers that increase surface area and promote cellular attachment. OSTEO GRAFT™? DBM Putty - a demineralized cortical bone graft with a cohesive, moldable consistency to support bone formation without synthetic carriers. OSTEO BRIDGE™? Sponge Strips - a sponge-like bone graft substitute that conforms to patient anatomy and fills bone voids to support structural regeneration. Each biologic is formulated from 100% allograft bone, free of synthetic carriers, delivering natural osteoconductive and osteoinductive properties for predictable, high-quality bone growth. Fully moldable and cohesive, these materials are designed to fill bony defects or augment fusion sites, providing a natural biologic scaffold for bone regeneration. Engineered to work synergistically with Aurora's implant technologies, the Aurora Biologics line creates a comprehensive, biologically active fusion environment that optimizes outcomes for both patients and surgeons.
お知らせ • Sep 18Aurora Spine Corporation Announces Launch of its DEXA-L™? Anterior Lumbar Interbody Fusion DeviceAurora Spine Corporation announced the official launch of its DEXA-L Anterior Lumbar Interbody Fusion Device, with the product being implanted in recent initial surgeries. DEXA-L is part of Aurora's patented DEXA Technology Platform, which is a series of products that are the world's first bone density matched implants. The DEXA-L, part of the DEXA Technology Platform, is a stand-alone device for anterior lumbar interbody fusion (ALIF) procedures and is the first of its kind in the world. It is the first spinal implant that is a bone-mimicking™? structural implant helping doctors match the implant to the patient's bone density and quality. Dr. Daniel Barba of San Diego, CA was the first surgeon to use the DEXA-L™? Stand Alone ALIF System in the United States. Dr. Barba stated "Each of my patients are unique. Now I can use a Stand-Alone ALIF cage tailored specifically to their needs. This novel technology allows me to match the modulus of the cage to the bone density of each of my patients. This has enabled me to expand my indications for lumbar fusion within patients that would normally not be a good candidate due to their poor bone quality. The DEXA- L Stand Alone ALIF system, promoting bone density matched DEXA™? Technology, marks another landmark advancement for spinal surgery from Aurora Spine. The company are excited to introduce another procedural solution that accommodates not only standard spine patients but the most challenging patients who are also in need of care. Patient specific options for spine surgery have been advancing over the last several years but not matching a patient's bone density was a glaring need for a significant number of patients. The CDC estimates that almost half of the US population over 50 years of age have low bone mass. This equates to millions of patients that need an implant that matches their bone density when having spine surgery. The DEXA- Ltd. Stand Alone ALIF System now allows surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as those who have normal bone density but still need surgery. The days of not matching an implant modulus to the patient are behind the company.
お知らせ • Jul 09Aurora Spine Corporation Announces Initial Surgeries Using its Aero Lumbar Fusion SystemAurora Spine Corporation announced initial surgeries using Aurora Spine's newest product, the AERO Lumbar Fusion System, have commenced. The minimally invasive procedures using the AERO were conducted by two different surgeons, one ortho surgeon and one interventionalist. The initial surgeries performed were procedures done on the lumbar part of the spine. The AERO MIS Lumbar Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations.
お知らせ • Jun 18Aurora Spine Corporation Announces the Upcoming Launch of DEXA-L™, A Standalone Anterior Lumbar Interbody Fusion (ALIF) System Built on the Same Award-Winning DEXA PlatformAurora Spine Corporation announced the upcoming fourth quarter 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the DEXA-L™ implant is designed to address the challenges of spinal fusion in patients with varying bone densities — especially those with osteoporosis. For decades, spinal implants were primarily developed for patients with healthy bone stock. However, these implants have demonstrated reduced performance in patients with low bone density, where traditional designs may lack sufficient bone-implant contact and fail to achieve long-term fixation. DEXA Technology™ directly addresses this clinical gap, offering a smart, density-matched solution for today’s diverse patient population.
お知らせ • May 20Aurora Spine Corporation to Report Q1, 2025 Results on May 22, 2025Aurora Spine Corporation announced that they will report Q1, 2025 results Pre-Market on May 22, 2025
お知らせ • Apr 24Aurora Spine Corporation to Report Q4, 2024 Results on Apr 28, 2025Aurora Spine Corporation announced that they will report Q4, 2024 results at 4:00 PM, US Eastern Standard Time on Apr 28, 2025
お知らせ • Apr 15+ 1 more updateAurora Spine Corporation, Annual General Meeting, Jun 16, 2025Aurora Spine Corporation, Annual General Meeting, Jun 16, 2025.
お知らせ • Apr 02Aurora Spine Corporation Announces Publication of Biomechanical Study Demonstrating Superiority of SiLO TFX™? Sacroiliac Joint Fusion SystemAurora Spine Corporation announced the publication of a new clinical study titled "Fixation of the Sacroiliac Joint: A Cadaver-Based Concurrent-Controlled Biomechanical Comparison of Posterior Interposition and Posterolateral Transosseous Techniques" in the journal Neurospine. The study evaluates the biomechanical performance of Aurora Spine's SiLO TFX™? MIS Sacroiliac Joint Fixation System compared to traditional posterolateral transosseous techniques. The SiLO TFX™? system is a minimally invasive solution designed for sacroiliac joint fusion, addressing conditions such as sacroiliac joint disruptions and degenerative sacroiliitis. The system includes a Transfixing-Cone, an ilium screw, a sacrum screw, and associated instrumentation, engineered to transfix the sacrum and ilium, thereby providing stability conducive to bony fusion. The SiLO TFX system is designed in accordance with the AO Principles of Fusion--providing mechanical stability, preserving vascular supply, minimizing soft tissue disruption, and promoting an optimal environment for bone healing by proper decortication and the use of bone graft. The study's findings indicate that the posterior interposition technique, as employed by the SiLO TFX system, removes less bone volume and offers a larger surface area for bony fusion compared to the posterolateral transosseal technique. Specifically, the posterior interposition technique resulted in a 42% +- 8% reduction in mutation/counternutation motion of the sacroiliac joint, outperforming the 14% +- 4% reduction observed with the posterolateral transosSEous technique. Furthermore, upon fatigue loading, the posterior interposition implant maintained the bone-implant interface across all specimens, whereas the posterolateral transos Seous implant inhibited migration or subsidence in 20%-50% of specimens.
お知らせ • Mar 25Aurora Spine Corporation Announces FDA 510(K) Clearance for the Aero™? Facet Fusion SystemAurora Spine Corporation announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's newest product, the AERO™? Facet Fusion System. The AERO MIS Facet Fusion System is a novel, patent-pending device designed to provide a minimally invasive solution for patients suffering from facet joint-related pain or instability. Cleared for use from spinal levels C2 to S1 (inclusive), the system can be used as a stand-alone facet fusion procedure or as an adjunct to larger spinal fusion surgeries. Engineered for earlier use in the continuum of care, AERO is ideal for patients experiencing mechanical back pain, minor instability, or degenerative joint disease who have not responded to conservative therapies. The system incorporates intuitive instrumentation and implant technology designed to promote bone fusion while minimizing soft tissue disruption--aligning with Aurora Spine's commitment to advancing patient-first, surgeon-friendly innovations. Initial surgeries utilizing the AERO system are expected to begin in late Third Quarter 2025, with several leading spine surgeons already selected to participate in an initial clinical study aimed at validating the device's clinical outcomes and long-term benefits.
お知らせ • Mar 10Aurora Spine Corporation Announces Completion of Enrollment in Groundbreaking REFINE StudyAurora Spine Corporation announced the completion of patient enrollment in its REFINE study of its ZIP™ Interspinous Fixation device for patients suffering from back pain due to symptomatic degenerative disc disease. This prospective, multi-center, multi-specialty clinical trial is the first of its kind to evaluate the safety and efficacy of lumbar interlaminar fusion devices, marking a significant milestone in the advancement of spinal care. The REFINE study, designed to bridge the gap between conservative treatments and more invasive surgical options, has successfully enrolled its full cohort of patients across multiple centers in the United States. Data from this pioneering study will be published out to one year, with a subsequent cohort publication extending to two years, offering robust, long-term insights into patient outcomes. The results will be presented at the American Society of Pain and Neuroscience (ASPN) annual conference in July 2025, spotlighting Aurora Spine's commitment to evidence-based innovation. Dr. Steven Anagnost, an orthopedic surgeon at Oklahoma Spine and Musculoskeletal Medicine, reflected this optimism: "The impact of the REFINE study cannot be overstated. As an orthopedic surgeon, I see firsthand the need for reliable, minimally invasive solut ions. This trial's comprehensive, multi-specialty approach will shape the future of spinal fusion, offering patients safer and more effective options backed by solid data." Dr. Jason Pope, a pain physician at Evolve Restorative Center in Santa Rosa, CA, highlighted the transformative potential of the study: "True innovation isn't just about new devices, it's about proving they work and delivering real benefits to patients. The REFINE study showcases how Aurora Spine is pushing boundaries, providing hope and tangible improvements for those suffering from debilitating back pain." Aurora Spine's REFINE study stands out for its collaborative design, uniting neurosurgeons, orthopedic surgeons, and interventional pain physicians to assess the ZIP™ MIS Interspinous Fusion System. This minimally invasive technology aims to address unmet needs in treating lumbar spinal stenosis and degenerative disc disease, offering patients a less invasive alternative to traditional spinal surgery. The Company anticipates that the REFINE study's findings will reinforce the efficacy and safety of its ZIP™ system, further solidifying Aurora Spine's position as a trailblazer in the spinal implant market. Aurora Spine remains committed to empowering physicians and improving patient outcomes through groundbreaking clinical evidence and minimally invasive solutions.
お知らせ • Jan 23Aurora Spine Corporation Announces the Promotion of Matt Paxton to Executive Vice President of SalesAurora Spine Corporation announced the promotion of Matt Paxton to Executive Vice President of Sales. As Executive Vice President of Sales, Mr. Paxton will spearhead company-wide initiatives, leveraging his expertise to drive operational excellence and strategic growth. Over the years, Mr. Paxton has demonstrated an unwavering commitment to Aurora Spine’s vision, playing a key role in fostering a culture of collaboration, innovation, and accountability.
お知らせ • Oct 16Aurora Spine Corporation Announces Release of Its Hydra Osteo Onyx Lumbar SystemAurora Spine Corporation announced it has launched its new OSTEO ONYX™ lumbar fusion system, promoting Rough Surface Technology (RST). The Hydra Osteo Onyx open and MIS systems give Surgeons the opportunity to treat patients who have osteopenia or osteoporosis, as well as their healthier patients. The Osteo Onyx roughened surface technology provides a great purchase within the pedicle that creates a benefit to patients with osteoporosis or poor bone quality. In addition, the range of MIS screws (4.5mm up to 10.5mm) allow its to accommodate any patient with a minimally invasive procedure which leads to better patient recovery and satisfaction.
お知らせ • May 01Aurora Spine Corporation to Report Q1, 2024 Results on May 13, 2024Aurora Spine Corporation announced that they will report Q1, 2024 results on May 13, 2024
お知らせ • Apr 23Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024Aurora Spine Corporation, Annual General Meeting, Jun 26, 2024.
お知らせ • Jan 18Aurora Spine Corporation to Showcase Sacroiliac Joint (Si Joint) Fusion Products At North American Neuromodulation Society Annual MeetingAurora Spine Corporation announced that it will be participating in the North American Neuromodulation Society (NANS) Annual Meeting from January 18-21 in Las Vegas, Nevada. The NANS Annual Meeting is a prominent medical conference that brings together healthcare professionals, researchers, and experts in the field of neuromodulation. Aurora will be showcasing two Sacroiliac Joint (SI Joint) fusion products. Silo TFX and Silo offer physicians options to stabilize the SI Joint, helping patients with access to treatment for their SI joint dysfunction. Aurora Spine will be presenting data from the recent publication of the first 6-month clinical evaluation from the REFINE Screwless™ ZIP™ Study of its ZIP Interspinous Fixation device in the Journal of Pain Research.
お知らせ • Dec 04Aurora Spine Corporation Announces Newly Published Paper on First 6-Month Clinical Evaluation of its ZIP™? Fusion ImplantAurora Spine Corporation announced the publication of the first 6-month clinical evaluation of its ZIP™? fusion implant in the Journal of Pain Research. Lumbar interlaminar decompression with interspinous fixation is an established safe and effective treatment for spinal stenosis. Early maintenance of improvements in pain intensity and function are critical for durability of symptom relief. The purpose of this study is to investigate the efficacy of minimally invasive treatments for low back pain during the early period after treatment and their utility in setting the course for longer term success. The scientific paper titled "Early Functional Outcomes in Low Back Pain Subjects with a Novel Interspinous fixation Device: REFINE Study 6-month Results", is a pivotal multi-center study of its ZIP™? InterspinousFixation device for patients suffering from back pain due to symptomatic degenerative disc disease and spinal stenosis. The REFINE Screwless™? ZIP Study utilized patient evaluations at 3- and 6-months following treatment and is part of an actively enrolling, institutional review board (IRB) approved, single-arm, multicenter, prospective, open-label 12-month study. Clinical efficacy was assessed primarily using the change from baseline in Oswestry Disability Index (ODI), Visual Analog Scale (VAS) of the back and leg pain during walking and standing, andurich Claudication Questionnaire (ZCQ), and secondarily using the Patient Global Impression of Change (PGIC) and Patient-Reported Outcomes Measurement Information System (PROMIS). This 6-month interim analysis at 42% enrollment of patients was conducted to determine prolonged safety and efficacy of the ZIP interspinous fusion device. Once in place, the device acts as a fusion support column to open the passageways that contain the spinal cord and nerve roots. This procedure may reduce the compression on the nerves, resulting in potential pain relief in the leg, groin, and buttocks, and then return to a more active lifestyle.
お知らせ • Oct 24Aurora Spine Corporation announced that it has received CAD 1.933782 million in fundingAurora Spine Corporation announced a non-brokered private placement to issue 6,445,939 Units at a price of CAD 0.30 per Unit for the gross proceeds of CAD 1,933,781.7 on October 3, 2023. Each Unit is comprised of one common share and one common share purchase warrant of the Company. Each whole warrant is exercisable at a price of CAD 0.50 per common share for a period of 24 months following the date of issuance. In connection with the Offering, the Company paid finder's fees in the amount of CAD 50,700 in the aggregate. The securities issued under the Offering will be subject to a four-month hold period in accordance with applicable securities legislation. The Offering is subject to TSX Venture Exchange final approval. The transaction included participation from certain directors of the Company.
お知らせ • Sep 14Aurora Spine Corporation Announces Full Release of its SiLO TFX™? MIS Sacroiliac Joint Fixation SystemAurora Spine Corporation announced that it is in full commercial release of its proprietary SiLO TFX™ MIS Sacroiliac Joint Fixation Device system. The patented, minimally invasive SiLO TFX MIS Sacroiliac Joint fixation System is intended for sacroiliac joint disruptions and degenerative sacroiliitis. The SiLO TFX MIS SacROiliac Joint Fixation System includes a Transfixing-Cone, an ilium screw, a sacrum screw and associated instrumentation. The SiLO TFX implants are designed to transfix the sacrum and ilium, providing stability forony fusion.
お知らせ • Jun 29Aurora Spine Corporation Announces Initial Patient Enrolled for DEXA-CTM Multicenter StudyAurora Spine Corporation announced that the first patient has been enrolled for its multicenter study of DEXA-CTM Cervical Interbody System. The commencement of the enrollment of patients indicates that the company has received all necessary approvals to launch the study, which will initially include data from 40 single level and 40 multiple level subjects. The DEXA-C system is indicated for anterior cervical interbody fusion procedures and is the first in a series of implants based on Aurora's patented DEXA™? technology platform. Based on the DEXA T-score for measuring a patient's bone density, the DEXA technology platform includes implants that are of varying densities to match a patient's bone density. DEXA-C is intended for use on patients who require anterior cervical discectomy and fusion surgery. The DEX A-C system implants an interbody spacer(s) into the cervical intervertebral body space(s) to stabilize and fuse the level(s). Allograft will be used in the spacer and the spinal segment(s) are fixed with an anterior cervical plate.
お知らせ • May 24Aurora Spine Corporation to Report Q1, 2023 Results on May 24, 2023Aurora Spine Corporation announced that they will report Q1, 2023 results on May 24, 2023
お知らせ • May 06Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023Aurora Spine Corporation, Annual General Meeting, Jun 28, 2023.
